Abbott received FDA approval for updates to its CardioMEMS HF System, enabling U.S. heart failure patients to view pulmonary artery pressure (PAP) readings on the new CardioGuide HF App. This app helps patients monitor their condition and receive personalized medication updates, allowing earlier intervention before symptoms worsen. The system, proven to reduce hospitalizations and mortality, now includes a Dynamic Treatment Plan feature that sends medication adjustments directly to patients. Abbott plans to launch these features later this year, enhancing patient engagement and care management between doctor visits.
Abbott Laboratories (ABT) shares are trading at USD 97.53 on Pluang as of Oct 05, 2026 20:12 WIB, showing a marginal 0.03% increase for the day. This price remains closer to its 52-week low of USD 82.57 than its 52-week high of USD 134.59, indicating room for growth relative to its yearly range. The stock's dividend yield stands at 2.58%, reflecting steady income potential alongside its market cap of $168.71 billion.
